SAN FRANCISCO — The “death squad for patents” has granted clemency to a branded drugmaker in the first inter partes review decision under the Hatch-Waxman Act.
The Patent Trial and Appeal Board (PTAB) ruled Tuesday that three patents held by Supernus Pharmaceuticals Inc. on a treatment for the skin condition rosacea are valid and not obvious.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
